Cite
HARVARD Citation
Rozeman, E. et al. (n.d.). LBA330 months relapse-free survival, overall survival, and long-term toxicity update of (neo)adjuvant ipilimumab (ipi) + nivolumab (nivo) in macroscopic stage III melanoma (OPACIN trial). Annals of oncology. p. . [Online].